Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions.
Saved in:
| Title: | Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions. |
|---|---|
| Authors: | Pierre CN; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Duke University School of Medicine, Durham, North Carolina, United States of America., Adams LE; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America., Higgins JS; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America., Anasti K; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America., Goodman D; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Surgery, Duke University School of Medicine, Durham, North Carolina, United States of America., Mielke D; Department of Surgery, Duke University School of Medicine, Durham, North Carolina, United States of America., Stanfield-Oakley S; Department of Surgery, Duke University School of Medicine, Durham, North Carolina, United States of America., Powers JM; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America., Li D; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America., Rountree W; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America., Wang Y; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America., Edwards RJ; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America., Alam SM; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America., Ferrari G; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Surgery, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, United States of America., Tomaras GD; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Surgery, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, United States of America.; Department of Immunology, Duke University, Durham, North Carolina, United States of America., Haynes BF; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Immunology, Duke University, Durham, North Carolina, United States of America., Baric RS; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America., Saunders KO; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Surgery, Duke University School of Medicine, Durham, North Carolina, United States of America.; Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, United States of America.; Department of Immunology, Duke University, Durham, North Carolina, United States of America. |
| Source: | PLoS pathogens [PLoS Pathog] 2024 Jun 20; Vol. 20 (6), pp. e1011569. Date of Electronic Publication: 2024 Jun 20 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN: 15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1553-7374 |
|---|---|
| DOI: | 10.1371/journal.ppat.1011569 |
